Viatris Inc Market Cap ($18.70 Billion)
Market Cap & Net Worth: Viatris Inc (VTRS)
Viatris Inc market cap. Viatris Inc (NASDAQ:VTRS) has a market capitalization of $18.70 Billion ($18.70 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1320 globally and #543 in its home market, demonstrating a 3.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Viatris Inc's stock price $19.04 by its total outstanding shares 1148590864 (1.15 Billion). Also see Viatris Inc (VTRS) cash conversion ratio for how efficiently the company converts equity into cash flow.
Viatris Inc Market Cap History (2015–2026)
Viatris Inc market cap history from 2015 to 2026. Data shows change from $53.83 Billion to $21.86 Billion (-6.05% CAGR). Check VTRS live share price for real-time trading data and today's change.
Index Memberships
Viatris Inc is a constituent of 5 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Pharmaceutical
DRG
|
$3.45 Trillion | 0.54% | #13 of 24 |
|
S&P 500 Index
GSPC
|
$61.47 Trillion | 0.02% | #375 of 503 |
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.72% | #23 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.05% | #162 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 1.02% | #16 of 263 |
Weight: Viatris Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Viatris Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Viatris Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Viatris Inc annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.00x
Viatris Inc's market cap is 1.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $37.98 Billion | $11.08 Billion | $480.00 Million | 3.43x | 79.13x |
| 2017 | $42.12 Billion | $11.91 Billion | $696.00 Million | 3.54x | 60.52x |
| 2018 | $27.28 Billion | $11.43 Billion | $352.50 Million | 2.39x | 77.39x |
| 2019 | $20.01 Billion | $11.50 Billion | $16.80 Million | 1.74x | 1191.16x |
| 2020 | $18.66 Billion | $11.95 Billion | -$669.90 Million | 1.56x | N/A |
| 2021 | $13.78 Billion | $17.89 Billion | -$1.27 Billion | 0.77x | N/A |
| 2022 | $11.81 Billion | $16.26 Billion | $2.08 Billion | 0.73x | 5.68x |
| 2023 | $12.06 Billion | $15.43 Billion | $54.70 Million | 0.78x | 220.43x |
| 2024 | $14.30 Billion | $14.74 Billion | -$634.20 Million | 0.97x | N/A |
| 2025 | $14.30 Billion | $14.30 Billion | -$3.51 Billion | 1.00x | N/A |
Competitor Companies of VTRS by Market Capitalization
Companies near Viatris Inc in the global market cap rankings as of November 1, 2026. Also see Viatris Inc asset portfolio for a full breakdown of the balance sheet.
Key companies related to Viatris Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Viatris Inc (2015–2026)
Market capitalization of Viatris Inc from 2015 to today. Between 2015 and today, Viatris Inc's market cap moved from $53.83 Billion to $ 21.86 Billion, with a yearly change of -6.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $21.86 Billion | +52.89% |
| 2025 | $14.30 Billion | 0.00% |
| 2024 | $14.30 Billion | +18.60% |
| 2023 | $12.06 Billion | +2.06% |
| 2022 | $11.81 Billion | -14.29% |
| 2021 | $13.78 Billion | -26.12% |
| 2020 | $18.66 Billion | -6.77% |
| 2019 | $20.01 Billion | -26.64% |
| 2018 | $27.28 Billion | -35.24% |
| 2017 | $42.12 Billion | +10.90% |
| 2016 | $37.98 Billion | -29.44% |
| 2015 | $53.83 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Viatris Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $18.70 Billion USD |
| MoneyControl | $18.70 Billion USD |
| MarketWatch | $18.70 Billion USD |
| marketcap.company | $18.70 Billion USD |
| Reuters | $18.70 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Viatris Inc
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and … Read more